Affordable Access

deepdyve-link
Publisher Website

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.

Authors
  • Catala, Gaetan1
  • Mebis, Jeroen2
  • Jerusalem, Guy3
  • Verhoeven, Didier4
  • Awada, Ahmad5
  • Bols, Alain6
  • Somers, Luc7
  • Van Den Broeck, Anke8
  • Duhoux, Francois P1
  • Machiels, Jean-Pascal1
  • 1 Department of Medical Oncology, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Institut Roi Albert II, Université catholique de Louvain, Brussels, Belgium. , (Belgium)
  • 2 Department of Medical Oncology, Jesse Ziekenhuis, Hasselt, Belgium. , (Belgium)
  • 3 Department of Medical Oncology, CHU Sart Tilman, Liège University, Liège, Belgium. , (Belgium)
  • 4 Department of Medical Oncology, Z Klina, Brasschaat, Belgium. , (Belgium)
  • 5 Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. , (Belgium)
  • 6 Department of Medical Oncology, AZ Sint Jan, Brugge, Belgium. , (Belgium)
  • 7 OncoLogX bvba, Antwerp, Belgium. , (Belgium)
  • 8 Oncology/Haematology, Amgen BeLux, Brussels, Belgium. , (Belgium)
Type
Published Article
Journal
Acta clinica Belgica
Publication Date
Apr 01, 2020
Volume
75
Issue
2
Pages
128–135
Identifiers
DOI: 10.1080/17843286.2018.1563735
PMID: 30609907
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Background: Chemotherapy plays an important role in the treatment of early breast cancer (EBC). Granulocyte-colony stimulating factors (G-CSF) can reduce the risk of febrile neutropenia as primary prophylaxis (PP) or secondary prophylaxis (SP). The BRONS study investigated the incidence of serious neutropenic events (SNE) and G-CSF use in a Belgian population of EBC patients treated with myelosuppressive polychemotherapy.Methods: Conducted in 2011, this study was a prospective, multicentre, observational trial involving 260 patients. The primary endpoint was the incidence of SNE defined as either febrile neutropenia (FN) or prolonged severe neutropenia (PSN; neutrophil count ≤0.5 × 10⁹ for at least five days). Secondary endpoints included a description of the chemotherapeutic regimens prescribed and G-CSF use.Results: Nine percent of patients were treated with a dose-dense regimen (DD) and 91% received classical chemotherapy (CC). PP with G-CSF (PPG) was given to 20% of patients (100% in DD and 11% in CC). Eighteen percent of patients presented a SNE (4% in DD and 20% in CC) of which 15% were FN and 3% PSN. SNE occurrence was 8% in the PPG subgroup and 21% in the no-PPG subgroup. In the DD subgroup, all patients received PPG and no FN was reported. Twenty six adverse events related to G-CSF were reported in 8.2% of patients and two of these were classified as severe.Conclusion: This observational study highlights the high incidence of SNE with CC regimens in patients who do not receive PPG. It also confirms the safe profile of DD regimens with G-CSF support.

Report this publication

Statistics

Seen <100 times